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Objective: Randomised controlled trials have shown the benefits of Early Supported Discharge 
(ESD) of stroke survivors. Our aim was to evaluate whether ESD is still beneficial when 
operating in the complex context of frontline healthcare provision. 
 
Design: We conducted a cohort study with quasi experimental design. A total of 293 
stroke survivors (transfer independently or with assistance of one, identified rehabilitation 
goals) within two naturally formed groups were recruited from two acute stroke units: 
‘ESD’ n=135 and ‘Non ESD’ n=158 and 84 caregivers. The ‘ESD’ group accessed either of 
two ESD services operating in Nottinghamshire, UK. The ‘Non ESD’ group experienced 
standard practices for discharge and onward referral. Outcome measures (primary: 
Barthel Index) were administered at baseline, 6 weeks, 6 months and 12 months.  
 
Results: The ESD group had a significantly shorter length of hospital stay (P=0.029) and 
reported significantly higher levels of satisfaction with services received (P<0.001). 
Following adjustment for age differences at baseline, participants in the ESD group ( n=71) 
had significantly higher odds (compared to the Non ESD group, n=85) of being in the ⩾90 
Barthel Index category at 6 weeks (OR = 1.557, 95% CI 2.579 to 8.733), 6 months (OR = 
1.541, 95% CI 2.617 to 8.340) and 12 months (OR 0.837, 95% CI 1.306 to 4.087) respectively 
in relation to baseline. Carers of patients accessing ESD services showed s ignificant 
improvement in mental health scores (P<0.01). 
 
Conclusion: The health benefits of ESD are still evident when evidence based models of these 
services are implemented in practice. 
  
Introduction 
There is strong evidence for the benefits of Stroke Early Supported Discharge (ESD) services: 
multidisciplinary teams that co-ordinate the transfer of care from hospital to home and 
provide specialist rehabilitation in the early stages back at home.1,2 Meta-analyses of 14 
randomised controlled trials (n=1957) have shown that Early Supported Discharge reduces the 
risk of death and dependency and leads to improvements in patient satisfaction levels, in 
addition to reducing hospital stay by 8 days.1,2 
On the strength of this evidence base, many countries, including England, now recommend 
the provision of Early Supported Discharge services in national stroke guidelines and policy 
documents. 3-7 What remains to be investigated however, is whether Early Supported Discharge 
is still beneficial when operating in the unpredictable and complex context of frontline 
healthcare provision.8 
Here we quantitatively investigate whether Early Supported Discharge services that have 
adopted an evidence based model9 do achieve what the meta-analyses suggested they would: 
to accelerate the return home of stroke survivors and produce equivalent or better outcomes 
for patients than conventional care. 
Methods 
Patients admitted to stroke units in Nottinghamshire, England, between November 2010 and 
February 2012, were screened for inclusion if they fulfilled the following eligibility criteria:9 clinical 
diagnosis of stroke; transfer independently or with assistance of one (i.e. mild to moderate stroke); 
identified rehabilitation goals, medically stable, and able and willing to sign informed consent. 
These criteria reflected the adopted practices of the two Early Supported Discharge services 
involved in this study. Stroke patients (and their carers) who were then referred to an Early 
Supported Discharge service, and stroke patients (and carers) who met the recommended eligibility 
criteria, but who did not get referred to an Early Supported Discharge service, were recruited to the 
study and written informed consent obtained. Researchers undertook baseline assessment 
within 14 days of stroke onset. 
Patients within the Early Supported Discharge or ‘ESD’ group accessed either of two Early 
Supported Discharge services. Both Early Supported Discharge services had adopted an evidence 
based model informed by an international consensus docu-ment,9,10 providing a stroke specialist 
intervention that consisted of prompt, co-ordinated discharge from hospital with the immediate 
provision of rehabilitative care. A multidisciplinary team offering co-ordinated physician, nursing, 
physiotherapy, occupational therapy, speech therapy, psychological intervention and social care 
support provided intensive, daily, stroke specialist rehabilitation in the patient’s home for up to 
six weeks. Onward referral to other healthcare services after the Early Supported Discharge 
intervention were organised as required. 
The ‘Non ESD’ group was formed of stroke patients who met eligibility criteria but were not 
referred to, or were unable to access, Early Supported Discharge services. Despite receiving care 
in the same hospital, their home and General Practitioner were based in a postcode not covered 
by the Early Supported Discharge service. These patients lived in the same counties as ESD 
patients (Nottinghamshire or Derbyshire) and experienced standard practices for discharge 
planning. 
Trained researchers measured outcomes at baseline and follow-up visits at 6 weeks, 6 months 
(26 weeks), and 12 months (52 weeks) post baseline assessment. The primary outcome measure 
was the Barthel Index,11 measuring functional independence of stroke survivors. Secondary 
measures were the Nottingham Extended Activities of Daily Living Scale (NEADL)12 and the 
General Health Questionnaire 28 (GHQ-28)13 to assess psychological wellbeing; Medical 
Outcomes Study Short Form-36 (SF-36)14 and the EuroQol Index (EQ5D)15 to measure quality of 
life. A satisfaction questionnaire (4 point likert scale) was used to assess perceived knowledge 
and satisfaction with information on stroke.16 Caregivers were asked to complete the GHQ-28, 
the SF-36 and the 
satisfaction questionnaire. The NEADL and carer outcomes were not included at baseline 
assessment. Permission was obtained from patients to access medical records stored on 
Hospital Trust and Primary Care Trust databases. 
We aimed for a sample size of n=110 per group17,18 to satisfy power of 80% at 5% detec-
tion level for the primary outcome measure (effect size difference of 2-7.5 points). Group 
homogeneity and hospital data were analysed using t-tests for continuous variables, Chi-
squared tests (χ2) for categorical variables and Mann-Whitney U tests for skewed data. 
Between group differences were tested using the Mann-Whitney U test, within group 
differences using the Friedman test and post-hoc analysis using Wilcoxon signed-rank tests 
with a Bonferroni correction applied. 
For the Generalized Estimating Equation modelling (GEE), fitting an exchangeable working 
correlation matrix, the dependent variable was categorised as binary; Barthel Index score of 90 
and above (⩾90) or below 90 (<90), using a logit link, due to its highly skewed nature (90 was 
the overall median Barthel Index score). Similarly, we categorised the demographic variable of 
age as <75 and ⩾75.1,2 
The GEE analysis was performed on a subgroup of patients determined by the interquartile 
range of age of the whole sample, to adjust for differences at baseline. All patients including 
those with incomplete sets of data and repeated measures were accounted for. Any missing 
values at follow-up were imputed using last-value-observed carried forward.19 Regression 
coefficients were calculated for the effects of ESD compared to Non ESD as β values and 
standard errors of either increasing or decreasing the likelihood of a participant being in 
either Barthel Index score category. The significance of the predictors (β values and standard 
errors) was estimated using the Wald test and the associated odds ratios were computed by 
taking the exponential of the β coefficients for each regression coefficient. We undertook 
sensitivity analyses by varying the binary Barthel threshold values to 85, 93, 95 and 90 
(median scores at each time point). All hypotheses were tested two sided, with a critical value 
of <0.05. SPSS version 20 was used for all analysis. 
Results 
Of the 293 participants that enrolled into the study, 258 completed the outcome assessments at 6 
weeks, 237 at 6 months and 226 at 12 months (Figure 1). The 6-week assessment was completed 
by 84 caregivers; the 6-month assessment by 71 caregivers; and the 12-month assessment by 64 
caregivers. 
The Non ESD patient group (n=158) included patients who accessed a community stroke 
rehabilitation team (n=59) or a neurorehabilitation outpatient therapy service (n=27). Patients 
who did not receive any services following discharge from hospital (n=72) were also included in 
this group of participants. 
Table 1 shows the demographic characteristics of the groups at baseline. The groups were 
similar with regard to Barthel Index scores, ethnicity and sex variables and number of days 
between stroke onset and baseline assessment. The ESD group were, on average, slightly 
younger than the Non ESD group. 
We found no significant differences between groups in mortality or number of readmissions to 
a stroke unit or general ward within 28 days or within 1 year of baseline assessment (Table 2). 
Patients referred to ESD had a significantly shorter average stay on hospital rehabilitation wards (0 
days versus 6.5 days; P=0.018) and a shorter total length of hospital stay (9 days versus 11 days; 
P=0.029). 
Between group comparisons of outcome measure data showed no significant differences between 
groups when compared at each individual time point. Analysis of questionnaire data (4 point likert 
scale, [median and interquartile range figures reported]) did however show that, at 6 weeks, the 
ESD group reported a significantly  higher of level of overall satisfaction with services [ESD 3(2-3), 
Non ESD 2(2-3) P<0.001], and more knowledge of reducing the risk of stroke [ESD 3(1-3), Non ESD 
2(1-3) P<0.01], practical help [ESD 2(1-3), Non ESD 1(0-3) P=0.01] and community services [ESD 3(2-
3), Non ESD 2(1-3) P<0.001].The ESD group also reported more knowledge of emotional support at 12 
months [ESD 1(0-3), Non ESD 0(0-1) P<0.001]. Both ESD and Non ESD patients improved sig-
nificantly over time (Table 3). For the non ESD group there was also a significant increase over 
time on the NEADL (P=0.037) and for the ESD group only, there were significant increases in 
quality of life as measured by the EuroQol Index (P=0.001) and the physical subcomponent 
summary scores (PSC) of the SF36 (P=0.01). To further explore changes over time in a non-
parametric repeated measures analysis, GEE modeling was conducted using the primary outcome 
measure, the Barthel Index, as the dependent variable Median (interquartile range in 
parentheses). Q: measure not administered at time point, BI: Barthel Index, PCS: Physical 
Component Summary Measure of SF36, MCS: Mental Health Component Summary Measure 
of SF36. Groups were compared using Friedman Test. *Significant at P<0.05. 
(Table 4). To adjust for significant differences in age between groups at baseline, a sample of the 
main cohort, determined by the interquartile age range (63-81) of the whole data set, was 
selected for analysis. Exploring combined within and between group effects, the interaction 
model (adjusted for covari-ates) showed that ESD group participants had significantly higher odds 
of being in the ⩾90 Barthel category at 6 weeks, 6 months and 12 months respectively in relation 
to baseline. Results remained consistent when different threshold values were investigated in 
sensitivity analysis, demonstrating the robustness of the model. 
Between group comparisons showed no significant differences between carers in ESD and 
Non ESD groups with regards to caregivers’ physical, mental and psychological wellbeing, and 
satisfaction and knowledge with stroke related services. There was a statistically significant 
improvement in mental health (SF-36 MCS; Table 5) over time in carers of patients that received 
ESD services (χ2 (2)=13.000, P=0.002). Post-hoc analysis showed a statistically significant 
improvement in mental health scores at 6 weeks and 6 months, compared to baseline in the 




We have shown that when adopting an evidence based model, Early Supported Discharge 
services can significantly reduce length of hospital stay and result in equivalent or better 
outcomes for mild to moderate stroke patients and their carers – benefits that were suggested 
by clinical trial data.1,2 We have also presented quantitative methodology that can be used 
when evaluating the effectiveness of evidence based innovations, such as Early Supported 
Discharge, outside of a randomised controlled trial setting.20 
Our principal finding was that Early Supported Discharge accelerated the recovery of mild to 
moderate stroke survivors, as measured by activities of daily living and the Barthel Index, over a one 
year period. That patients in the Non ESD group also showed recovery over time is perhaps not 
surprising, given that many of them accessed other rehabilitative care via in-hospital or via out-
patient services. What is important is that ESD patients showed a steeper recovery trajectory. A 
methodological issue worth noting is that this was only brought to light by modeling changes over 
time (interaction effects) and adjusting for covariates. This would have been overlooked by the use 
of static, between group, analyses at each time point only (which resulted in a lack of main effect of 
group in the GEE modelling). 
Whereas both ESD and Non ESD patients showed significant improvements over time in sec-
ondary outcome measures of general health and quality of life, at the 6 week follow up point, 
ESD 
patients were significantly more satisfied with services and had increased knowledge of risk, 
practical help and community services. In addition, carers of patients accessing Early 
Supported Discharge services showed significant improvements over time in the mental health 
component of the SF-36. This goes some way to negate earlier fears that ESD may have a 
negative impact on carers.1,2,9,21 
In addition to these benefits, patients in the ESD group had a significantly shorter time in 
hospital compared to Non ESD patients, the latter spending significantly more time on 
rehabilitation wards. That this was only a difference of 2 days (compared to the 8 days referred 
to in previous meta-analyses), could be explained by the overall reduction in length of hospital 
stay of all stroke patients since the original randomised controlled trials were conducted and the 
fact that the Non ESD group did have access to further rehabilitation services other than ESD at 
discharge. 
Reduction in length of hospital stay originally made Early Supported Discharge attractive from an 
economic perspective. The idea that Early Supported Discharge services could be funded entirely 
by a reduction in length of hospital stay, we suggest, is overly optimistic. Cost savings from a 
reduction in length of hospital stay also need to be realised within the funding arrangements 
associated with healthcare provision in that country – and ‘tariff’ unbundling in the UK has proved 
problematic. 
A limitation of this study is that not all patients, accessing the two Early Supported Discharge ser-
vices we studied, were recruited to this study. There was a slower stream of patients (not involved 
in this study) who took longer (than the 14-days post stroke recruitment window used) to reach 
eligibility criteria for the two services. Whilst our results highlight the benefits of ‘early’ Early 
Supported Discharge to a cohort of mild to moderate patients, whether such benefits are evident 
for patients who accessed the service later post-stroke remains to be investigated. 
Another limitation of this study was its quasi experimental nature. It was important that patients 
in the Non ESD group did not differ systematically from those in the ESD group. Eligibility criteria 
used by researchers to recruit patients to this study (and in particular to the Non ESD group) 
needed to be the same as criteria adopted by the two Early Supported Discharge services in 
practice. Groups did end up differing significantly in age, although we adjusted for this in our 
statistical modeling. Also, patients in the Non ESD group lived in a postcode not served by the 
ESD services included in the study. Whilst we are confident that both ESD and Non ESD cohorts 
were representative of the Nottinghamshire and Derbyshire population served by the acute 
hospitals involved in this study, there may have been other demographic differences between 
the groups that were not measured. 
Lastly there is the question of whether findings are transferrable. The critical factor is that both 
services in this study adopted a service model informed by an international Early Supported 
Discharge consensus document.9,10 We suggest that because these services have adopted core 
components of an evidenced base service, the benefits of Early Supported Discharge were realised. 
This study builds on an already strong evidence base demonstrating the benefits of Early 
Supported Discharge services for stroke survivors both in terms of reducing length of hospital 
stay and accelerating recovery at home. This, in addition to the wealth of policy and national 
guideline recommendations, makes it hard to understand why Early Supported Discharge 
services are not accessible to all eligible patients both in the UK and abroad. 
Clinical message 
 Patients who received care from an evidence based Early Support Discharge service, 
gained the benefits anticipated from randomised controlled trials, when compared with 
patients who did not access the service. 
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7 Deaths 
Total 14 
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Figure 1. Flow of participants through study. 
Table 1. Baseline characteristics of participants. 
  
Variable ESD (n=135) Non ESD (n=158) P value 
Age, median (IQR) ††† 71(62–79) 76(65.75–82) 0.005* 
N days between stroke 
onset and baseline 
assessment, mean (SD) 
†† 
7(7) 6(6) 0.503 
Gender †    
Women, n (%) 45(33.3%) 56 (35.4%) 0.705 
Male, n (%) 90(66.6%) 102(64.6%)  
Baseline BI, median (IQR) 80 (65–95) 85 (70–95) 0.174 
†††    
Ethnicity†    
White, n (%) 127(94%) 155 (98.1%) 0.068 
Other, n (%) 8 (6%) 3 (1.9%)   
†Groups were compared using χ2 for ethnicity and gender. ††Groups were compared using t-test for N 
days between stroke onset and baseline assessment. †††Groups were compared using Mann Whitney U 
Test for age and baseline Barthel score. *Significant at P<0.05. 
Table 2. Clinical hospital data. 
   
Variable ESD (n=135) Non ESD (n=158) P value 
Total LOS acute, median††† 4(2–7) 3(2–5.8) 0.061 
(IQR)    
Total LOS rehab, median 0(0–12) 6.5(0–15.8) 0.018* 
(IQR) †††    
Total LOS (rehab + 
acute stay), median 
(IQR) ††† 
9(4–18.3) 11(5–21.0) 0.029* 
Readmitted to SU within 2(1.5%) 1(0.7%) 0.606 
28 days hospital 
discharge, n (%)† 
   
Readmitted to Gen 
ward within 28 days of 
hospital discharge, n 
(%)† 
12(9.2%) 11(7.7%) 0.669 
Readmitted to SU within 
1 year baseline 
assessment, n (%)† 
18(13.8%) 10 (7.0%) 0.073 
Readmitted to Gen 
ward within 1 year 
baseline assessment, n 
(%)† 
47 (36.0%) 62 (43.4%) 0.266 
Case fatality, n (%)† 11 (8.5%) 16 (11.2%) 0.544 
 
†Groups were compared using χ2 for readmissions and case fatality. †††Groups were compared using Mann 
Whitney U Test for length of hospital stay. 
*Significant at P<0.05. Figures provided rounded to one decimal place. 
  
Table 3. Comparison of patient outcomes: Within group comparison.  
 
Group Variable n Baseline 6 Weeks 6 Months 12 Months P 
ESD BI 110 80(65–91) 95(84–100) 95(80–100) 90(75–100) 0.000* 
 NEADL 110 Q 35(24–49) 39(27–50) 31.5(18–46) 0.146 
 GHQ-28 108 25(18–35) 22(16–34) 19(12–30) 18.5(13–29) 0.000* 
 SF36-PCS 108 32.9(24.3–39.9) 32.4(25.4–42.4) 33.9(22.9–47.1) 31.7(21.3–43.1) 0.010* 
 SF36-MCS 108 50.3(38.8–58.7) 47.1(35.7–55.3) 52.4(43.9–58.1) 53.3(44.2–60.2) 0.000* 
 EuroQol 110 0.74(0.65–0.84) 0.78(0.7–0.88) 0.77(0.68–1.00) 0.77(0.65–0.88) 0.001* 
 Index       
 EuroQol 110 55(45–70) 60(50–80) 65(50–80) 70(50–80) 0.000* 
 Imaginable       
 Health       
NonESD BI 109 85(70–95) 90(80–100) 95(80–100) 95(75–100) 0.000* 
 NEADL 109 Q 35(24–52) 36(24.5–54) 36(20–50.5) 0.037* 
 GHQ-28 108 23(17–31) 22(16–29) 19.5(14–25) 20(13–26) 0.001* 
 SF36-PCS 108 35.1(28.3–43.3) 34.5(26.3–42.9) 33.3(24.8–43.9) 35.3(24.1–45.8) 0.413 
 SF36-MCS 108 51.3(43.6–58.0) 47.9(34.4–57.1) 54.1(45.8–58.5) 53.5(48.1–59.1) 0.006* 
 EuroQol 110 0.75(0.68–0.88) 0.77(0.69–0.88) 0.77(0.68–0.88) 0.77(0.69–0.88) 0.711 
 Index       
 EuroQol 110 60(50–80) 65(50–80) 70(50–80) 75(50-85) 0.002* 
 Imaginable       
 Health        
  
Table 4. Generalized estimating equation modelling: Barthel Index scores at 6 (n=139), 26 (n=133) and 52 
(n=127) weeks using baseline (n=156) as point of reference. 
 Parameter β Std. Error OR 95% CI P value 
Model A: 
main effects 
     
 Gender 0.155 0.2734 1.167 0.683–1.995 0.572 
 Ethnicity 0.054 0.6855 1.055 0.275–4.044 0.938 
 Age –0.259 0.2607 0.772 0.463–1.287 0.321 
 Group –0.208 0.2663 0.812 0.482–1.369 0.436 
 Time6Weeks 1.154 1.936 3.172 2.170–4.636 0.000* 
 Time26Weeks 1.103 0.2048 3.013 2.017–4.500 0.000* 
 Time52Weeks 0.793 0.2067 2.210 1.474–3.314 0.000* 






–0.941 0.3969 0.390 0.179–0.850 0.018* 
 Group *Age –0.246 0.4111 0.782 0.349–1.750 0.550 
 Group 1.557 0.3112 4.745 2.579–8.733 0.000* 
 *Time6Weeks     
 Group 1.541 0.2957 4.671 2.617–8.340 0.000* 
 *Time26Weeks     
 Group 0.837 0.2910 2.311 1.306–4.087 0.004* 
 *Time52Weeks     
*Significant at P<0.05.   
Table 5. Comparison of carer outcomes: Within group comparison. 
  
Group Variable n 6 Weeks 6 Months 12 Months P 
ESD GHQ-28 26 18.5(14.5–27) 17(14.75–20.5) 19.5(11.75–26.25) 0.512 
 SF36-PCS 26 47.2(35.7–
56.1) 
46.2(35.9–55.9) 44.8(35.9–55.9) 0.341 
 SF36-MCS 26 44.6(37.8–
51.1) 
54(50–57.4) 51.1(44.–56.7) 0.002* 
NonESD GHQ-28 26 15.5(12–26) 19(13–30.25) 15.5(11.5–31) 0.282 
 SF36-PCS 26 48.3(36.3–
55.7) 
48.3(36.3–55.7) 46.8(36.2–55.3) 0.060 
 SF36-MCS 26 46.1(34.8–
55.8) 
50.8(37.3–57.9) 52.6(41.0–57.1) 0.076 
 
Median (interquartile range in parentheses). Groups were compared using Friedman Test. *Significant at P<0.05. 
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